Unia Europejska - bułgarski - EMA (European Medicines Agency)

novo nordisk a/s - инсулин degludec, лираглутид - Захарен диабет тип 2 - Лекарства, използвани при диабет - xultophy е показан за лечение на възрастни с тип 2 захарен диабет да подобряване на гликемичния контрол в комбинация с перорални глюкозо понижаващи лекарствени продукти, когато тези самостоятелно или в комбинация с glp-1 рецепторен агонист или базален инсулин не предоставят адекватни гликемичния контрол.

Unia Europejska - bułgarski - EMA (European Medicines Agency)

novo nordisk a/s - инсулин degludec - Захарен диабет - Лекарства, използвани при диабет - Лечение на захарен диабет при възрастни.

Unia Europejska - bułgarski - EMA (European Medicines Agency)

novo nordisk a/s - инсулин аспарт - Захарен диабет - Лекарства, използвани при диабет - Лечение на захарен диабет.

Unia Europejska - bułgarski - EMA (European Medicines Agency)

astrazeneca ab - метформина хидрохлорид, Саксаглиптин, dapagliflozin - Захарен диабет тип 2 - Лекарства, използвани при диабет - qtrilmet е показан при възрастни на възраст 18 и повече години с диабет тип 2, за подобряване на гликемичния контрол при метформином или без сульфонилмочевины (Су) и саксаглиптин или dapagliflozin не осигурява адекватен гликемичен контрол . когато вече лекувани с метформин и саксаглиптин и dapagliflozin.

Unia Europejska - bułgarski - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - Лекарства, използвани при диабет - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 и 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.

Unia Europejska - bułgarski - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - Захарен диабет тип 2 - Лекарства, използвани при диабет - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Unia Europejska - bułgarski - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - Захарен диабет тип 2 - Лекарства, използвани при диабет - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Bułgaria - bułgarski - Изпълнителна агенция по лекарствата

stada arzneimittel ag - Пиоглитазон - 15 mg tablets

Bułgaria - bułgarski - Изпълнителна агенция по лекарствата

stada arzneimittel ag - Пиоглитазон - 30 mg tablets

Bułgaria - bułgarski - Изпълнителна агенция по лекарствата

stada arzneimittel ag - Пиоглитазон - 45 mg tablets